Can-Fite BioPharma (CANF)
Dawson James analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma on January 5 and set a price target of $7.00. The company’s shares closed last Tuesday at $1.09, close to its 52-week low of $0.94.
According to TipRanks.com, Kolbert is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Can-Fite BioPharma with a $7.00 average price target, a 530.6% upside from current levels. In a report issued on January 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CANF: